CA3067489A1 - Crystalline form of n-[1-(5-cyano-pyridin-2-ylmethyl)-1 h-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide - Google Patents

Crystalline form of n-[1-(5-cyano-pyridin-2-ylmethyl)-1 h-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide Download PDF

Info

Publication number
CA3067489A1
CA3067489A1 CA3067489A CA3067489A CA3067489A1 CA 3067489 A1 CA3067489 A1 CA 3067489A1 CA 3067489 A CA3067489 A CA 3067489A CA 3067489 A CA3067489 A CA 3067489A CA 3067489 A1 CA3067489 A1 CA 3067489A1
Authority
CA
Canada
Prior art keywords
degree
crystalline form
pyrazol
trifluoromethyl
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3067489A
Other languages
English (en)
French (fr)
Inventor
Bibia Heidmann
Markus von Raumer
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CA3067489A1 publication Critical patent/CA3067489A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3067489A 2017-07-05 2018-07-04 Crystalline form of n-[1-(5-cyano-pyridin-2-ylmethyl)-1 h-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide Pending CA3067489A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2017066806 2017-07-05
EPPCT/EP2017/066806 2017-07-05
PCT/EP2018/068087 WO2019008034A1 (en) 2017-07-05 2018-07-04 CRYSTALLINE FORM OF N- [1- (5-CYANO-PYRIDIN-2-YLMETHYL) -1H-PYRAZOL-3-YL] -2- [4- (1-TRIFLUOROMETHYL-CYCLOPROPYL) -PHENYL] -ACETAMIDE

Publications (1)

Publication Number Publication Date
CA3067489A1 true CA3067489A1 (en) 2019-01-10

Family

ID=63079885

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3067489A Pending CA3067489A1 (en) 2017-07-05 2018-07-04 Crystalline form of n-[1-(5-cyano-pyridin-2-ylmethyl)-1 h-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide

Country Status (17)

Country Link
US (2) US11059803B2 (https=)
EP (1) EP3649117B1 (https=)
JP (2) JP2020525475A (https=)
KR (1) KR102645911B1 (https=)
CN (1) CN110831932A (https=)
AU (1) AU2018296423B2 (https=)
BR (1) BR112020000099A2 (https=)
CA (1) CA3067489A1 (https=)
CL (1) CL2020000002A1 (https=)
EA (1) EA202090193A1 (https=)
IL (1) IL271764B2 (https=)
MA (1) MA50972A (https=)
MY (1) MY206357A (https=)
PH (1) PH12020500040A1 (https=)
SG (1) SG11201912881SA (https=)
UA (1) UA126582C2 (https=)
WO (1) WO2019008034A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110072521B (zh) 2016-12-16 2022-11-29 爱杜西亚药品有限公司 包含t型钙通道阻断剂的药物组合
MA47409A (fr) 2017-02-06 2019-12-11 Idorsia Pharmaceuticals Ltd Nouveau procédé de synthèse de 1-aryl-1-trifluorométhylcyclopropanes
EP3649117B1 (en) * 2017-07-05 2024-10-09 Idorsia Pharmaceuticals Ltd Crystalline form of n -[1-(5-cyano-pyridin-2-ylmethyl)-1 h -pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide
TW202128158A (zh) 2019-12-20 2021-08-01 瑞士商愛杜西亞製藥有限公司 包含n-[1-(5-氰基-吡啶-2-基甲基)-1h-吡唑-3-基]-2-[4-(1-三氟甲基-環丙基)-苯基]-乙醯胺之醫藥組合物
EP4389892A4 (en) * 2021-08-17 2025-12-10 Korea Advanced Inst Sci & Tech Antisense oligonucleotide targeting the CAV3.1 gene and its uses
WO2023240205A1 (en) 2022-06-10 2023-12-14 Neurocrine Biosciences, Inc. Deuterated compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6195684B2 (ja) * 2014-06-03 2017-09-13 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ピラゾール化合物及びｔ型カルシウムチャンネルブロッカーとしてのそれらの使用
WO2016041892A1 (en) 2014-09-15 2016-03-24 Actelion Pharmaceuticals Ltd Triazole compounds as t-type calcium channel blockers
CN110072521B (zh) 2016-12-16 2022-11-29 爱杜西亚药品有限公司 包含t型钙通道阻断剂的药物组合
MA47409A (fr) 2017-02-06 2019-12-11 Idorsia Pharmaceuticals Ltd Nouveau procédé de synthèse de 1-aryl-1-trifluorométhylcyclopropanes
EP3649117B1 (en) * 2017-07-05 2024-10-09 Idorsia Pharmaceuticals Ltd Crystalline form of n -[1-(5-cyano-pyridin-2-ylmethyl)-1 h -pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide

Also Published As

Publication number Publication date
US20210300894A1 (en) 2021-09-30
KR20200018698A (ko) 2020-02-19
EA202090193A1 (ru) 2020-06-03
MA50972A (fr) 2020-10-14
CL2020000002A1 (es) 2020-07-31
IL271764A (en) 2020-02-27
EP3649117B1 (en) 2024-10-09
US11555025B2 (en) 2023-01-17
IL271764B1 (en) 2023-06-01
SG11201912881SA (en) 2020-01-30
JP2020525475A (ja) 2020-08-27
US11059803B2 (en) 2021-07-13
AU2018296423A1 (en) 2020-02-20
JP2023123679A (ja) 2023-09-05
BR112020000099A2 (pt) 2020-07-07
MY206357A (en) 2024-12-12
KR102645911B1 (ko) 2024-03-08
US20200165221A1 (en) 2020-05-28
CN110831932A (zh) 2020-02-21
IL271764B2 (en) 2023-10-01
WO2019008034A1 (en) 2019-01-10
UA126582C2 (uk) 2022-11-02
EP3649117A1 (en) 2020-05-13
AU2018296423B2 (en) 2022-07-28
PH12020500040A1 (en) 2020-10-12

Similar Documents

Publication Publication Date Title
US11555025B2 (en) Crystalline form of N-[1-(5-cyano-pyridin-2-ylmethyl)-1 H-pyrazol-3-yl]-2- [4-(1-trifluoromethyl-cyclopropyl)-phenyl-acetamide
JP7068188B2 (ja) インダゾールの合成
EP3634956B1 (en) Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
KR20210114972A (ko) 치환된 피롤리딘 아마이드 iii
JP6916207B2 (ja) インダゾールの合成
US20220275011A1 (en) Crystalline forms
CN110372562B (zh) 一种btk激酶抑制剂关键中间体的晶型及其制备方法
CA2904079C (en) A process for preparation of (2s,5r)-7-oxo-6-sulphooxy-2-[((3r)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo-[3.2.1]-octane
KR20180005252A (ko) 화합물 (s)-3-｛4-[5-(2-시클로펜틸-6-메톡시-피리딘-4-일)-[1,2,4]옥사디아졸-3-일]-2-에틸-6-메틸-페녹시｝-프로판-1,2-디올의 결정형
US11103512B2 (en) Crystalline form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol
EP4582086A2 (en) Clazosentan disodium salt, its preparation and pharmaceutical compositions comprising the same
HK40009744B (en) Crystalline forms
KR20220124752A (ko) 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)-1h-피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4,4-디메틸펜트-2-엔니트릴의 결정 형태
NZ750772B2 (en) Crystalline forms
NZ746469B2 (en) Synthesis of indazoles

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230629

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240813

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20241213

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260219